FDA Approves ZORYVE® Foam 0.3%: A New Topical Option for Scalp and Body Psoriasis
In a significant development for psoriasis treatment, the U.S. Food and Drug Administration (FDA) has approved ZORYVE® (roflumilast) topical foam 0.3%, for the treatment of plaque psoriasis, including intertriginous areas, in adults and pediatric patients aged 12 years and older. This approval offers a new, steroid-free, once-daily topical therapy for patients with psoriasis affecting the […]
New Findings in Molecular and Structural Properties of IL-23 Inhibitors: A Breakthrough in Psoriasis TreatmentÂ
Biologics that inhibit the pro-inflammatory cytokine IL-23 have long been regarded as important therapies in the treatment of psoriasis. However, much is still unknown about the molecular mechanisms that drive clinical efficacy. In this study, researchers sought to uncover the key driving factors by analyzing several IL-23 inhibitors in the treatment of psoriasis. Their findings, […]
